サンプル依頼リスト カート
  • English
  • Korean
表紙：基底細胞がん治療の世界市場レポート 2024年
市場調査レポート
商品コード
1415647

基底細胞がん治療の世界市場レポート 2024年

Basal Cell Carcinoma Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
基底細胞がん治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

基底細胞がん治療の市場規模は近年急速に拡大しています。2023年の66億9,000万米ドルから2024年には74億2,000万米ドルに、CAGR10.8％で成長します。実績期間の成長は、皮膚がんの有病率の増加、レーザー治療の需要、効果的で低侵襲な治療に対する需要、基底細胞がん治療の認知度の高まりに起因します。

基底細胞がん治療市場規模は、今後数年間で力強い成長が見込まれます。2028年の年間平均成長率（CAGR）は9.8％で、107億7,000万米ドルに成長します。予測期間の成長は、QOL重視の高まり、高齢化、免疫療法の研究開発拡大、政府の取り組みなどが背景にあります。予測期間における主な動向には、治療方法の進歩、早期発見技術、標的療法の進歩、遠隔医療統合などがあります。

皮膚がん、特に基底細胞がんの発生が増加していることが、今後の治療市場の成長を促進すると予想されます。皮膚がんは、皮膚における異常細胞の制御不能な増殖を特徴とし、多くの場合、太陽や日焼け装置からの紫外線（UV）への曝露と関連しています。皮膚がん、特に基底細胞がんの有病率の増加は、標的を絞った特殊な治療オプションの必要性を強調し、この特定のがんタイプに対処するために調整された効果的な薬剤の開発と利用可能性を促進しています。例えば、2023年1月、米国がん協会（American Cancer Society, Inc.）は、米国では毎年約540万人の基底細胞がんと扁平上皮がんが発生し、約330万人が罹患し、基底細胞がんは10件中8件を占めると報告しました。その結果、基底細胞がんを含む皮膚がんの罹患率の増加は、治療市場の成長を刺激することになります。

世界の高齢者人口の増加は、基底細胞がん治療市場の成長の原動力になると予測されています。高齢者人口」とは、一般的に65歳以上の個人を指し、このグループは、BCCの主要な危険因子である日光への長時間暴露により、基底細胞がん（BCC）に対してより脆弱です。その結果、高齢化による感受性の高まりは、BCCの診断と治療に対する需要の増加に寄与しています。例えば、2022年7月の国連経済社会局のデータでは、65歳以上の世界人口の割合は2022年の10％から2050年には16％に上昇すると予測されています。したがって、世界の高齢者人口の増加は、基底細胞がん治療市場成長の主要な促進要因です。

2023年の基底細胞がん治療市場では北米が最大地域でした。アジア太平洋は予測期間中に最も急成長する地域と予想されます。基底細胞がん治療レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東およびアフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の基底細胞がん治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 手術
  • 薬剤
  • その他の治療
  • 世界の基底細胞がん治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • その他
  • 世界の基底細胞がん治療市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • 世界の基底細胞がん治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • その他

第7章 地域および国の分析

  • 世界の基底細胞がん治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の基底細胞がん治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 基底細胞がん治療市場の競合情勢
  • 基底細胞がん治療市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co. Inc.
    • AbbVie Inc.
    • Bayer AG

第31章 その他の主要および革新的な企業

  • Novartis AG
  • Sanofi SA
  • Fresenius Kabi AG
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Perrigo Company PLC
  • Incyte Corporation
  • Ono Pharma UK Ltd

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12246

“Basal Cell Carcinoma Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on basal cell carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for basal cell carcinoma treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The basal cell carcinoma treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Treatment: Surgery; Medication; Other Treatments
  • 2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
  • 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 4) By End-User: Hospitals; Specialty Clinics; Other End-Users
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Basal cell carcinoma (BCC) is a form of skin cancer originating from basal cells, which are responsible for generating new skin cells. It often appears as a small, translucent lump but can have varied presentations. Effective treatment strategies for basal cell carcinoma (BCC) involve tumor removal, considering tumor characteristics, location, size, patient preferences and the practicality of follow-up appointments.

The main types of basal cell carcinoma treatment are surgery, medication and other treatments. Surgery refers to a branch of medicine that involves treating diseases and conditions through operative or manual procedures, including cutting, abrading, suturing, or otherwise physically changing body tissues and organs and surgeries are also vital for basal cell carcinoma patients, removing tumors to achieve effective treatment and minimize damage. The treatments options are administered by oral, parenteral and other routes and are distributed through hospital pharmacy, online pharmacy and retail pharmacy channels for end users such as hospitals, specialty clinics and others.

The basal cell carcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides basal cell carcinoma treatment market statistics, including basal cell carcinoma treatment industry global market size, regional shares, competitors with a basal cell carcinoma treatment market share, detailed basal cell carcinoma treatment market segments, market trends and opportunities and any further data you may need to thrive in the basal cell carcinoma treatment industry. This basal cell carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The basal cell carcinoma treatment market size has grown rapidly in recent years. It will grow from $6.69 billion in 2023 to $7.42 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to increasing prevalence of skin cancer, demand for laser therapy, demand for effective and minimally invasive treatments, rising awareness of basal cell carcinoma treatment.

The basal cell carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $10.77 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to growing focus on quality of life, aging population, growing research and development in immunotherapies, government initiatives. Major trends in the forecast period include advancements in treatment modalities, early detection technologies, advancements in targeted therapies, telemedicine integration.

The increasing occurrences of skin cancer, notably basal cell carcinoma, are anticipated to drive growth in the treatment market in the future. Skin cancer is characterized by the uncontrolled growth of abnormal cells in the skin, often linked to exposure to ultraviolet (UV) radiation from the sun or tanning devices. The growing prevalence of skin cancer, particularly basal cell carcinoma, underscores the need for targeted and specialized treatment options, driving the development and availability of effective medications tailored to combat this specific cancer type. For example, in January 2023, the American Cancer Society, Inc., reported that the United States witnessed approximately 5.4 million cases of basal and squamous cell skin cancer each year, affecting around 3.3 million individuals, with basal cell carcinoma accounting for eight out of every ten cases. Consequently, the increasing incidence of skin cancer, including basal cell carcinoma, is poised to stimulate growth in the treatment market.

The global increase in the elderly population is anticipated to act as a driving force behind the growth of the basal cell carcinoma treatment market. The term 'geriatric population' pertains to individuals typically aged 65 and older, and this group is more vulnerable to basal cell carcinoma (BCC) due to prolonged sun exposure, a primary risk factor for BCC. Consequently, the aging population's heightened susceptibility contributes to a greater demand for the diagnosis and treatment of BCC. For instance, data from the United Nations Department of Economic and Social Affairs in July 2022 predicts that the percentage of the global population aged 65 and above is set to rise from 10% in 2022 to 16% by 2050. Hence, the increasing geriatric population worldwide is a key driver for the growth of the basal cell carcinoma treatment market.

The high expenses related to therapeutics for basal cell carcinoma have the potential to exert an adverse impact on the growth of the basal cell carcinoma treatment market. These elevated costs create a barrier to the adoption of advanced treatments and limit access to care. Furthermore, the high price tags may hinder new market entrants and encourage established companies to innovate and differentiate their products. For example, in September 2023, according to the US-based National Library of Medicine, the average retail price for a standard prescription of imiquimod, a common treatment for basal cell carcinoma, is $118.08. The treatment cost for a giant basal cell carcinoma using radiation can range from $465 to $3,311, while vismodegib treatment can reach as high as $139,560. Consequently, the high expenses linked to basal cell carcinoma therapeutics present an obstacle to the growth of the basal cell carcinoma treatment market.

Leading companies in the basal cell carcinoma treatment market are dedicated to pioneering innovative technologies to address unmet medical needs in the field of oncology and fortify their market presence. For example, in February 2021, Regeneron Pharmaceuticals Inc., a US-based biopharmaceutical firm, and Sanofi SA, a France-based healthcare company, secured approval for Libtayo (cemiplimab-rwlc), a PD-1 inhibitor, marking it as the first immunotherapy treatment for individuals with advanced basal cell carcinoma (BCC). Libtayo's development leverages Regeneron's VelocImmune technology, a groundbreaking approach that uses a genetically engineered mouse platform with a genetically humanized immune system to produce highly effective human antibodies. Libtayo's historic approval stems from its demonstrated clinical benefits in advanced BCC cases post-HHI therapy, with comprehensive local and accelerated metastatic approvals contingent on trial assessments encompassing response rate, durability, and clinical benefit validation.

In July 2022, Regeneron Pharmaceuticals Inc., a US-based biopharmaceutical company, secured exclusive licensing rights to Libtayo from Sanofi SA for a sum of $900 million. This acquisition strengthens Regeneron Pharmaceuticals, Inc.'s presence in the field of oncology by granting it the rights to develop, market, and manufacture Libtayo, a prescription medication designed for the treatment of individuals with cutaneous squamous cell carcinoma (CSCC) and advanced basal cell carcinoma, two types of skin cancer. Sanofi SA, a pharmaceutical firm headquartered in France, is responsible for the development of the basal cell carcinoma treatment drug, Libtayo.

Major players in the basal cell carcinoma treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Fresenius Kabi AG, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Incyte Corporation, Ono Pharma UK Ltd., Cipla Inc., Lupin Limited, Mallinckrodt Pharmaceuticals, LEO Pharma A/S, BeiGene Ltd., Taro Pharmaceutical Industries Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Genentech USA Inc., Palvella Therapeutics LLC.

North America was the largest region in the basal cell carcinoma treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in basal cell carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the basal cell carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The basal cell carcinoma treatment market consists of revenues earned by entities by providing surgical excision, Moh's surgery, cryosurgery, photodynamic therapy (PDT) and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The basal cell carcinoma treatment market also includes sales of topical treatment and advanced medication. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Basal Cell Carcinoma Treatment Market Characteristics

3. Basal Cell Carcinoma Treatment Market Trends And Strategies

4. Basal Cell Carcinoma Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Basal Cell Carcinoma Treatment Market Size and Growth

  • 5.1. Global Basal Cell Carcinoma Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Basal Cell Carcinoma Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Basal Cell Carcinoma Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Basal Cell Carcinoma Treatment Market Segmentation

  • 6.1. Global Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Surgery
  • Medication
  • Other Treatments
  • 6.2. Global Basal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Other Route Of Administrations
  • 6.3. Global Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.4. Global Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Other End-Users

7. Basal Cell Carcinoma Treatment Market Regional And Country Analysis

  • 7.1. Global Basal Cell Carcinoma Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Basal Cell Carcinoma Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Basal Cell Carcinoma Treatment Market

  • 8.1. Asia-Pacific Basal Cell Carcinoma Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Basal Cell Carcinoma Treatment Market

  • 9.1. China Basal Cell Carcinoma Treatment Market Overview
  • 9.2. China Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Basal Cell Carcinoma Treatment Market

  • 10.1. India Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Basal Cell Carcinoma Treatment Market

  • 11.1. Japan Basal Cell Carcinoma Treatment Market Overview
  • 11.2. Japan Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Basal Cell Carcinoma Treatment Market

  • 12.1. Australia Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Basal Cell Carcinoma Treatment Market

  • 13.1. Indonesia Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Basal Cell Carcinoma Treatment Market

  • 14.1. South Korea Basal Cell Carcinoma Treatment Market Overview
  • 14.2. South Korea Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Basal Cell Carcinoma Treatment Market

  • 15.1. Western Europe Basal Cell Carcinoma Treatment Market Overview
  • 15.2. Western Europe Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Basal Cell Carcinoma Treatment Market

  • 16.1. UK Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Basal Cell Carcinoma Treatment Market

  • 17.1. Germany Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Basal Cell Carcinoma Treatment Market

  • 18.1. France Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Basal Cell Carcinoma Treatment Market

  • 19.1. Italy Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Basal Cell Carcinoma Treatment Market

  • 20.1. Spain Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Basal Cell Carcinoma Treatment Market

  • 21.1. Eastern Europe Basal Cell Carcinoma Treatment Market Overview
  • 21.2. Eastern Europe Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Basal Cell Carcinoma Treatment Market

  • 22.1. Russia Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Basal Cell Carcinoma Treatment Market

  • 23.1. North America Basal Cell Carcinoma Treatment Market Overview
  • 23.2. North America Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Basal Cell Carcinoma Treatment Market

  • 24.1. USA Basal Cell Carcinoma Treatment Market Overview
  • 24.2. USA Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Basal Cell Carcinoma Treatment Market

  • 25.1. Canada Basal Cell Carcinoma Treatment Market Overview
  • 25.2. Canada Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Basal Cell Carcinoma Treatment Market

  • 26.1. South America Basal Cell Carcinoma Treatment Market Overview
  • 26.2. South America Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Basal Cell Carcinoma Treatment Market

  • 27.1. Brazil Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Basal Cell Carcinoma Treatment Market

  • 28.1. Middle East Basal Cell Carcinoma Treatment Market Overview
  • 28.2. Middle East Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Basal Cell Carcinoma Treatment Market

  • 29.1. Africa Basal Cell Carcinoma Treatment Market Overview
  • 29.2. Africa Basal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Basal Cell Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Basal Cell Carcinoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Basal Cell Carcinoma Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Basal Cell Carcinoma Treatment Market Competitive Landscape
  • 30.2. Basal Cell Carcinoma Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bayer AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Basal Cell Carcinoma Treatment Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi SA
  • 31.3. Fresenius Kabi AG
  • 31.4. AstraZeneca PLC
  • 31.5. GlaxoSmithKline PLC
  • 31.6. Eli Lilly and Company
  • 31.7. Gilead Sciences Inc.
  • 31.8. Merck KGaA
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Regeneron Pharmaceuticals Inc.
  • 31.11. Bausch Health Companies Inc.
  • 31.12. Sun Pharmaceutical Industries Ltd.
  • 31.13. Perrigo Company PLC
  • 31.14. Incyte Corporation
  • 31.15. Ono Pharma UK Ltd

32. Global Basal Cell Carcinoma Treatment Market Competitive Benchmarking

33. Global Basal Cell Carcinoma Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Basal Cell Carcinoma Treatment Market

35. Basal Cell Carcinoma Treatment Market Future Outlook and Potential Analysis

  • 35.1 Basal Cell Carcinoma Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Basal Cell Carcinoma Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Basal Cell Carcinoma Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer